Multiple myeloma--complete remission with high dose melphalan chemotherapy.

Area of Science:

• Oncology
• Hematology
• Pharmacology

Background:

• Multiple myeloma is a plasma cell malignancy often presenting with anemia, hypercalcemia, renal insufficiency, and bone lesions.
• IgG3 lambda subtype is a specific and less common variant of plasma cell myeloma.
• Standard treatment protocols for multiple myeloma involve chemotherapy, including melphalan.

Observation:

• A patient diagnosed with IgG3 lambda plasma cell myeloma received a significantly higher dose of intravenous melphalan than typically administered.
• The patient exhibited characteristic symptoms including anemia, hypercalcemia, hypoalbuminemia, renal insufficiency, and osteolytic bone lesions.
• Serum and urinary light chain levels were monitored as indicators of disease activity.

Findings:

• Following the high-dose melphalan administration, the patient achieved a complete remission of the myeloma.
• Remission was evidenced by normalization of serum protein levels and bone marrow studies.
• Radiographic evidence showed healing of previously identified osteolytic bone lesions.

Implications:

• This case, along with similar rare instances, suggests that higher doses of melphalan might induce complete remissions in multiple myeloma.
• The findings could have significant ramifications for future chemotherapeutic strategies in treating multiple myeloma.
• Further investigation into dose-escalation protocols for melphalan in specific myeloma subtypes may be warranted.